Tuam Tshoj High Purity 98% Peptides Powder Liraglutide CAS 204656-20-2 Peptides Powder hauv Vials uas tsis muaj nqi zoo nkauj peptides Tshuaj pleev ib ce raw khoom

Liraglutide (NN2211) yog qhov ua haujlwm ntev glucagon zoo li peptide-1 receptor agonist. Ua lag luam raws li lub npe lag luam Victoza, nws yog cov tshuaj txhaj tshuaj tsim los ntawm Novo Nordisk rau kev kho mob ntshav qab zib hom 2. Hauv xyoo 2015, Novo Nordisk tau pib ua lag luam hauv Tebchaws Meskas raws li lub npe liraglutide raws li kev kho mob rau cov neeg laus uas muaj tsawg kawg yog ib qho kev hnyav hnyav.

Kev siv kho mob

Liraglutide yog ib qho tshuaj txhaj ib hnub ib zaug ntawm tib neeg incretin (metabolic hormone) glucagon-zoo li peptide-1 (GLP-1), rau kev kho mob ntshav qab zib hom 2 lossis rog rog.

Hom 2 Ntshav Qab Zib

Liraglutide txhim kho kev tswj cov ntshav qabzib. Kev ncua lub plab zom mov, thiab txo qis prandial glucagon secretion.

Nyob rau hauv ntau yam nrog rau lwm yam GLP-1 receptor agonists, liraglutide muaj qhov zoo dua li kev kho mob ntau dua rau hom 2 mob ntshav qab zib:

Nws muaj peev xwm inhibiting apoptosis thiab stimulating regeneration ntawm beta hlwb (pom nyob rau hauv cov kev tshawb fawb tsiaj).

Nws txo qis qab los noj mov thiab inhibits lub cev qhov hnyav nce, raws li qhia hauv kev tshawb fawb taub hau rau glimepiride.

Nws txo qis cov ntshav triglyceride.

Kev rog rog

Liraglutide tau raug pom zoo raws li kev txhaj tshuaj ntxiv rau kev noj zaub mov kom tsawg thiab ua kom lub cev muaj zog ntxiv rau kev tswj qhov hnyav hauv cov neeg laus. Cov txheej txheem teev tseg yog qhov pib lub cev qhov hnyav (BMI) ntawm 30 kg / m2 lossis ntau dua (obese), lossis 27 kg / m2 lossis ntau dua (hnyav), nyob rau hauv muaj tsawg kawg yog ib qho kev hnyav hnyav (xws li kub siab, hom 2 mob ntshav qab zib mellitus, lossis dyslipidemia). Thaum xyoo 2014 lig, cov ntaub ntawv tau tshaj tawm los ntawm SCALE™ Obesity thiab Prediabetes sim, uas yog ib qho randomised, ob qhov muag tsis pom kev, cov placebo-tswj, ntau lub teb chaws sim hauv cov neeg tsis muaj ntshav qab zib uas muaj rog thiab cov neeg tsis muaj ntshav qab zib uas rog rog nrog comorbidities. Hauv theem 3a sim no, muaj 3,731 tus neeg koom nrog randomized rau kev kho mob nrog liraglutide 3 mg lossis placebo, ob qho tib si nrog kev noj haus thiab kev tawm dag zog. Cov neeg uas ua tiav 56-lub lim tiam sim ua tiav qhov hnyav poob ntawm 9.2%, piv nrog 3.5% txo qis hauv pawg placebo.